Law Offices of Thomas J. Lamb, P.A.

Law Offices of Thomas J. Lamb, P.A. Blogs

Blog Authors

Latest from Law Offices of Thomas J. Lamb, P.A.

New Warnings Added To Drug Labels For All VEGF Inhibitors By UK’s MHRA Already; FDA Is Evaluating Need For Regulatory Action   (Posted by Tom Lamb at DrugInjuryWatch.com)   On July 31, 2020 the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) issued this Drug Safety Update, “Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection“, which began as follows: Before initiating systemic vascular endothelial growth factor (VEGF) pathway…
Woman Developed Acute And Severe Loss Of Visual Acuity Following Her Second Beovu Injection   (Posted by Tom Lamb at DrugInjuryWatch.com)   Beovu (brolucizumab) was approved by the FDA in 2019 for the treatment of neovascular (wet) age-related macular degeneration (AMD).  Since then there have been reports of Beovu-associated vision loss and blindness due to occlusive retinal vasculitis, retinal artery occlusion, and intraocular inflammation.  For example, we point out a Beovu retinal vasculitis case…
Current Findings On Risks Of Occlusive Vasculitis And Vision Loss Following Beovu Injections For Treatment Of Wet AMD   (Posted by Tom Lamb at DrugInjuryWatch.com)   According to news reports, Beovu safety issues were a dominant topic at the American Society of Retina Specialists (ASRS) annual meeting which was held virtually July 24-26, 2020. In particular, the ASRS Research and Safety in Therapeutics (ReST) committee discussed possible Beovu side effects such as the risk…
Picato Skin Cancer Risk Has Been Confirmed By European Drug Regulator; The FDA Is Still Investigating This Picato Safety Issue   (Posted by Tom Lamb at DrugInjuryWatch.com)   The topical gel drug Picato (ingenol mebutate), which is prescribed for the treatment of actinic keratosis, or solar keratosis, has been under the scrutiny of drug regulators around the world since the start of 2020.  While the FDA is still investigating the Picato skin cancer risk,…
New Vision-Related Side Effects Warnings For Beovu Eye Injections Have Been Added In US, Australia, And Switzerland, Thus Far   (Posted by Tom Lamb at DrugInjuryWatch.com)   In this recent article, “Beovu Label Change: Warnings About Possible Permanent Vision-Loss Side Effects Added In June 2020“, we pointed out that the HAWK & HARRIER clinical trials was a significant factor leading to the new warnings for Beovu eye injections about retinal vasculitis and…
Beovu Use Increased Risks of Retinal Vasculitis And Retinal Vascular Occlusion, Which Can Lead To Blindness   (Posted by Tom Lamb at DrugInjuryWatch.com)   In early June 2020, the FDA approved a label update for Beovu (brolucizumab) whereby Novartis will add warnings and safety information about retinal vasculitis and retinal vascular occlusion, which can lead to loss of vision. This FDA regulatory action comes after postmarketing reports of these Beovu vision-loss side effects in…
Levels Of NDMA In Zantac Pills Can Cause These Cancer: Stomach, Colon, Rectal, Bladder, Kidney, Pancreatic   (Posted by Tom Lamb at DrugInjuryWatch.com)   On April 1, 2020, the FDA announced that it was requesting a Zantac recall due to the presence of a contaminant known as N-Nitrosodimethylamine (NDMA) in Zantac and all other medications containing ranitidine. This fact that there is NDMA in Zantac and other ranitidine medications is significant because NDMA is…
Patients On Belviq Developing Cancer File Lawsuits Against Responsible Drug Company For Failure To Warn   (Posted by Tom Lamb at DrugInjuryWatch.com)   The Belviq recall announced in February 2020 after the FDA concluded that the potential risk of cancer associated with Belviq (lorcaserin) outweighs its benefits. The FDA noted there was a numerical imbalance in the number of patients on Belviq developing cancer, then pointed out pancreatic cancer, colorectal cancer, and lung cancer,…
Lemtrada Side Effects Range From Drug-Induced Autoimmune Complications To Cardiovascular Reactions   (Posted by Tom Lamb at DrugInjuryWatch.com)   Medical researchers in Switzerland recently presented the case of a 26-year-old man who developed life-threatening anti-neutrophil cytoplasmic autoantibody (ANCA) systemic vasculitis after being treated with Lemtrada (alemtuzumab) for relapsing-remitting multiple sclerosis. This case report about Lemtrada causing ANCA-associated vasculitis adds to the growing number of autoimmune complications which can be regarded as Lemtrada side effects.…
FDA Investigation Of This Picato Drug Safety Issue Seems To Be Still Ongoing, Despite Picato Recall In Europe   (Posted by Tom Lamb at DrugInjuryWatch.com)   A European drug safety panel announced in April 2020 that a Picato increased risk of skin cancer findings outweigh Picato’s benefits as a treatment of actinic keratosis. On January 27, 2020 we posted this article, “Picato Skin Cancer Risk Investigation By European Drug Regulator Prompts Sales Suspension